Thinking Inside the Box - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Thinking Inside the Box
A modular approach to biopharmaceutical production could bring process flexibility, and contract manufacturing organizations are beginning to take notice.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 34-40

What's in it for CMOs?


Disposable downstream equipment such as chromatography columns is being accepted and validated for commercial processes. PHOTO: COURTESY OF GE HEALTHCARE
CMOs are likely to benefit most from modular manufacturing, particularly when they use disposable components, says Mani Krishnan, director for Mobius single-use processing systems at Millipore (Billerica, MA). CMOs always must be ready to produce various molecules that require distinct processes, and they must be able to produce materials at various scales. A modular manufacturing facility can be reconfigured ra-pidly to meet the needs of the molecule. CMOs that use this approach thus can apply Lean strategies to respond quickly to particular customers' changing needs and change over between different customers' projects easily. This flexibility can help CMOs increase their output and reduce their costs.

Even before production begins, a modular approach can be beneficial because it simplifies validation. The CMO's burden is less to begin with because the equipment vendor has already started the validation work. Furthermore, a CMO can perform process validation more easily and with less work if it involves one unit operation at a time instead of two, three, or four connected together. The chances of demonstrating consistency by completing three perfect batches are greater for one operation than for many, says Galliher.

Modular manufacturing enhances a CMO's speed and flexibility in the production of modern vaccines, monoclonal antibodies, and novel biomolecules entering the clinic. A company can design a modular facility that accommodates various kinds of bioreactors (e.g. for mammalian cells or for bacteria) and manufactures at several scales. Disposable components make it possible to dedicate a modular facility to a single product (e.g., recombinant proteins, monoclonal antibodies, or vaccines) or to allow it to produce multiple products as required, says Grund.

If properly designed, a modular process could help a CMO to increase the number of contracts it can execute in one plant simultaneously. Ordinarily, a plant might have five or six unit operations in a row that are all dedicated to one client or to one cleanroom. But a CMO can install enclosed, modular unit operations to enable it to serve five clients in the same room, each in its own module. This arrangement would give a CMO five times the revenue with the same manufacturing group that it had before. "That gives us a huge multiplier on profits, margins, and revenue capability," says Galliher.

This approach works because the enclosed module becomes the cleanroom, and the module often can conserve valuable plant space. For example, the FlexFactory from Xcellerex has a footprint that is 35–40% smaller than a traditional cleanroom facility that includes gowning areas and access hallways, according to Galliher. The cost of a gray space with cleanroom modules is also lower than that of a conventional cleanroom.

On the other hand, the initial development costs for modular equipment often are higher than those for traditional machines, and this factor might prevent some companies from taking a modular approach, says Trudeau. Yet CMOs ultimately have a strong incentive for embracing the technique because it increases their speed to market, he adds.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here